Brokerages Expect Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to Post -$1.81 Earnings Per Share
Equities research analysts predict that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will post earnings per share of ($1.81) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Alnylam Pharmaceuticals’ earnings, with estimates ranging from ($2.28) to ($1.58). Alnylam Pharmaceuticals posted earnings of ($1.61) per share in the same quarter last year, which would indicate a negative year over year growth rate of 12.4%. The firm is expected to report its next quarterly earnings report on Thursday, August 1st.
On average, analysts expect that Alnylam Pharmaceuticals will report full year earnings of ($7.41) per share for the current financial year, with EPS estimates ranging from ($8.42) to ($6.62). For the next year, analysts anticipate that the business will post earnings of ($6.43) per share, with EPS estimates ranging from ($7.75) to ($4.90). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.20) by $0.47. The firm had revenue of $33.29 million for the quarter, compared to the consensus estimate of $21.60 million. Alnylam Pharmaceuticals had a negative net margin of 929.51% and a negative return on equity of 55.33%. Alnylam Pharmaceuticals’s quarterly revenue was up 52.0% compared to the same quarter last year. During the same period last year, the firm posted ($1.22) EPS.
NASDAQ:ALNY traded up $0.21 during mid-day trading on Wednesday, hitting $70.13. The stock had a trading volume of 16,463 shares, compared to its average volume of 928,686. The company has a market cap of $7.53 billion, a PE ratio of -9.25 and a beta of 2.58. The company has a quick ratio of 9.12, a current ratio of 9.33 and a debt-to-equity ratio of 0.20. Alnylam Pharmaceuticals has a 52 week low of $60.27 and a 52 week high of $124.21.
In other news, Director Philip A. Sharp sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $88.23, for a total value of $1,323,450.00. Following the transaction, the director now owns 250,633 shares of the company’s stock, valued at approximately $22,113,349.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John Maraganore sold 49,457 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $70.00, for a total transaction of $3,461,990.00. Following the completion of the transaction, the chief executive officer now directly owns 239,450 shares in the company, valued at approximately $16,761,500. The disclosure for this sale can be found here. Insiders own 3.60% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Meeder Asset Management Inc. increased its position in shares of Alnylam Pharmaceuticals by 332.9% in the first quarter. Meeder Asset Management Inc. now owns 342 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 263 shares in the last quarter. US Bancorp DE increased its position in shares of Alnylam Pharmaceuticals by 66.2% in the first quarter. US Bancorp DE now owns 369 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 147 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new position in shares of Alnylam Pharmaceuticals in the first quarter worth approximately $47,000. Quadrant Capital Group LLC increased its position in shares of Alnylam Pharmaceuticals by 543.2% in the first quarter. Quadrant Capital Group LLC now owns 521 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 440 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its position in shares of Alnylam Pharmaceuticals by 268.9% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 701 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 511 shares in the last quarter. 89.78% of the stock is currently owned by institutional investors.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.
Featured Story: Analyzing a company’s cash flow statement
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.